Business
Change of Joint Broker
Cambridge Cognition Holdings plc has announced the immediate appointment of Singer Capital Markets as Joint Corporate Broker, following the transfer of Dowgate Capital's corporate broking, advisory, and research team to Singer Capital Markets. This change in brokerage is the primary focus of the announcement and may impact how the company's shares are covered and traded. Disclaimer*
About this update from Cambridge Cognition Holdings Plc
09 February 2026 Cambridge Cognition Holdings plc ("Cambridge Cognition", the "Company" or the "Group") Change of Joint Broker Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces the appointment of Singer Capital Markets as Joint Corporate Broker with immediate effect following the transfer of Dowgate Capital's corporate broking, advisory and research team to Singer Capital Markets. For further information, please contact: Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer Tel: 01223 810700 [email protected] Panmure Liberum Limited (NOMAD and Joint Broker) Will Goode / Mark Rogers / Freddy Crossley Rupert Dearden Tel: 020 7886 2968 (Corporate Finance) (Corporate Broking) Singer Capital Markets (Joint Broker) Amber Higgs / James Serjeant / Daniel Ingram Tel: 020 7496 3000 Notes to Editors About Cambridge Cognition Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care. Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors: · Clinical Studies for new pharmaceuticals; · Academic Research for scientists to understand CNS disorders; · Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and, · Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health. For further information, visit: www.cambridgecognition.com
View stock analysis, news, and events for Cambridge Cognition Holdings Plc